SCHEMBL19586751

SCHEMBL19586751

Nc1ccc2ncn(C3CCC(=O)NC3=O)c2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 19/20 1.00
DDB1 Q16531 17/20 1.00
IKZF3 Q9UKT9 5/20 1.00
ALDH1A1 P00352 1/20 0.42
CHRM2 P08172 1/20 0.42
OPRM1 P35372 1/20 0.42
CYP1A2 P05177 1/20 0.42
TSHR P16473 1/20 0.42
TDP1 Q9NUW8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20812213 0.92 CRBN (1.00) CRBNDDB1IKZF3ALDH1A1CHRM2
Hydrochloric Acid SCHEMBL31520821 0.91 CRBN (0.97) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL19586745 0.86 CRBN (0.76) CRBNDDB1IKZF3
SCHEMBL27241621 0.85 CRBN (0.73) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL25653901 0.85 CRBN (0.73) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL23065972 0.85 CRBN (0.73) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL25654122 0.85 CRBN (0.73) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL19586175 0.84 CRBN (0.76) CRBNDDB1IKZF3
SCHEMBL20812400 0.81 CRBN (1.00) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL19586686 0.81 CRBN (0.67) CRBNDDB1IKZF3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250127903-A1 SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2025-04-24 US disclosed
US-12048747-B2 Substituted piperidine Degronimers for Target Protein degradation C4 THERAPEUTICS, INC. (US) 2024-07-30 US disclosed
US-20230265116-A1 DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE BEONE MEDICINES I GMBH (CH) 2023-08-24 US disclosed
US-20220313827-A1 SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2022-10-06 US disclosed
EP-3455219-A1 AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 Therapeutics, Inc. (US) 2019-03-20 EP disclosed
US-20190076539-A1 AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 Theraprutics, Inc. (US) 2019-03-14 US disclosed
US-20190076539-A1 AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 Theraprutics, Inc. (US) 2019-03-14 US disclosed
WO-2017197051-A1 AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2017-11-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265116-A1 DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE EGFR, CBL, ERBB2 CRBN 144/4885DDB1 438/4885IKZF3 999/4885
US-20250127903-A1 SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION STUB1, UBE3C, NEDD4 CRBN 77/4885DDB1 769/4885IKZF3 2159/4885
US-20190076539-A1 AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION GCGR, STUB1, GID4 CRBN 23/4885DDB1 503/4885IKZF3 3499/4885
US-20220313827-A1 SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION STUB1, UBE3C, NEDD4 CRBN 77/4885DDB1 769/4885IKZF3 2159/4885
US-12048747-B2 Substituted piperidine Degronimers for Target Protein degradation GID4, RNF5, UBE3C CRBN 105/4885DDB1 716/4885IKZF3 2272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.